Mirvetuximab soravtansine

Generic Name
Mirvetuximab soravtansine
Brand Names
Elahere
Drug Type
Biotech
Chemical Formula
-
CAS Number
1453084-37-1
Unique Ingredient Identifier
98DE7VN88D
Background

Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine). DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1.
...

Indication

Mirvetuximab soravtansine is indicated for the treatment of adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test.
...

Associated Conditions
Platinum-resistant Epithelial Ovarian Cancer, Platinum Resistant Primary Peritoneal Cancer, Platinum drug resistant Fallopian tube cancer
Associated Therapies
-
Clinical Trials
Related News

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

First Posted Date
2024-11-11
Last Posted Date
2024-11-11
Lead Sponsor
AbbVie
Target Recruit Count
110
Registration Number
NCT06682988

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

First Posted Date
2024-04-15
Last Posted Date
2024-12-17
Lead Sponsor
AbbVie
Target Recruit Count
100
Registration Number
NCT06365853
Locations
🇺🇸

New York Oncology Hematology - Albany Cancer Center /ID# 269345, Albany, New York, United States

🇺🇸

Women'S Cancer Care Associates /ID# 269980, Albany, New York, United States

🇺🇸

Norton Healthcare /ID# 269070, Louisville, Kentucky, United States

and more 8 locations

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

First Posted Date
2023-06-05
Last Posted Date
2024-05-06
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
53
Registration Number
NCT05887609
Locations
🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

First Posted Date
2022-11-21
Last Posted Date
2022-11-21
Lead Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Target Recruit Count
35
Registration Number
NCT05622890
Locations
🇨🇳

Hubei Cancer Hospital, Wuhan, Hubei, China

🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

🇨🇳

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

and more 25 locations

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

First Posted Date
2022-07-13
Last Posted Date
2024-11-19
Lead Sponsor
AbbVie
Target Recruit Count
125
Registration Number
NCT05456685
Locations
🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States

and more 67 locations

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)

First Posted Date
2021-09-13
Last Posted Date
2024-12-20
Lead Sponsor
AbbVie
Target Recruit Count
79
Registration Number
NCT05041257
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

The University of Alabama at Birmingham - Division of Gynecology Oncology O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States

🇺🇸

Alaska Women's Cancer Care/Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 75 locations

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

First Posted Date
2020-03-05
Last Posted Date
2024-08-07
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
106
Registration Number
NCT04296890
Locations
🇺🇸

St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States

🇦🇺

St John of God Subiaco Hospital, Subiaco, Western Australia, Australia

🇮🇱

Shaare Zedek Medical Center, Jerusalem, Israel

and more 86 locations

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

First Posted Date
2020-02-18
Last Posted Date
2024-10-21
Lead Sponsor
AGO Research GmbH
Target Recruit Count
136
Registration Number
NCT04274426
Locations
🇩🇪

Charite Campus Virchow Klinikum, Berlin, Germany

🇩🇪

Städtische Klinikum Dessau, Dessau, Germany

🇩🇪

Universitätsklinikum Carl-Gustav-Carus an der Technischen Universität Dresden, Dresden, Germany

and more 17 locations

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

First Posted Date
2019-12-24
Last Posted Date
2024-11-19
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
453
Registration Number
NCT04209855
Locations
🇺🇸

Illinois Cancer Specialists, Arlington Heights, Illinois, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

and more 210 locations

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

First Posted Date
2019-02-11
Last Posted Date
2019-06-27
Lead Sponsor
University of Oklahoma
Registration Number
NCT03836157
Locations
🇺🇸

Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy